Literature DB >> 25798801

Will an Asymptomatic Meningioma Grow or Not Grow? A Meta-analysis.

Lingcheng Zeng1, Pei Liang2, Jiantong Jiao1, Jian Chen1, Ting Lei1.   

Abstract

BACKGROUND: The treatment strategy for patients with an asymptomatic meningioma is still controversial. Key to an optimal decision is a careful evaluation of the growth possibilities of the meningioma by taking the patient's clinicoradiologic factors into consideration. However, previous studies have disagreed about the risk factors relating to tumor growth.
METHODS: A comprehensive search of PubMed, Embase, and the ISI Web of Knowledge was performed. Using a meta-analysis with nine subsidiary studies including 777 patients, we analyzed the correlation of the growth pattern of meningioma with patient gender, tumor location, tumor calcification, magnetic resonance imaging (MRI) T2 signal intensity, and peritumoral brain edema.
RESULTS: The growth rate of meningioma was negatively correlated with tumor calcification (odds ratio [OR]: 0.23; 95% confidence interval (CI), 0.11-0.46; p < 0.001) but positively associated with MRI T2 signal intensity (OR: 2.75; 95% CI, 1.75-4.33; p < 0.001). No correlations were found between tumor growth and other factors such as gender (OR: 1.29; 95% CI, 0.84-1.99; p = 0.24), skull base location (OR: 0.80; 95% CI, 0.25-2.58; p = 0.70), and peritumoral brain edema (OR: 1.24; 95% CI, 0.29-5.27; p = 0.77).
CONCLUSIONS: Two factors, tumor calcification and low MRI T2 signal intensity, indicate the possibility of a slow growth meningioma. In such cases of asymptomatic meningioma, a follow-up strategy can be preferentially considered. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2015        PMID: 25798801     DOI: 10.1055/s-0034-1543959

Source DB:  PubMed          Journal:  J Neurol Surg A Cent Eur Neurosurg        ISSN: 2193-6315            Impact factor:   1.268


  7 in total

Review 1.  Dural masses: meningiomas and their mimics.

Authors:  Daniel Lyndon; Joseph A Lansley; Jane Evanson; Anant S Krishnan
Journal:  Insights Imaging       Date:  2019-02-06

2.  Natural History of Meningiomas: Review with Meta-analyses.

Authors:  Satoshi Nakasu; Yoko Nakasu
Journal:  Neurol Med Chir (Tokyo)       Date:  2020-01-31       Impact factor: 1.742

3.  A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas.

Authors:  Abdurrahman I Islim; Ruwanthi Kolamunnage-Dona; Midhun Mohan; Richard D C Moon; Anna Crofton; Brian J Haylock; Nitika Rathi; Andrew R Brodbelt; Samantha J Mills; Michael D Jenkinson
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

4.  MAC-spinal meningioma score: A proposal for a quick-to-use scoring sheet of the MIB-1 index in sporadic spinal meningiomas.

Authors:  Johannes Wach; Motaz Hamed; Tim Lampmann; Ági Güresir; Frederic Carsten Schmeel; Albert J Becker; Ulrich Herrlinger; Hartmut Vatter; Erdem Güresir
Journal:  Front Oncol       Date:  2022-08-26       Impact factor: 5.738

5.  Primary Extracranial Fibrous Meningioma of the Maxillary Sinus: A Case Report and Literature Review.

Authors:  Hyunwoo Cho; Sanghyeon Kim; Myongjin Kang; DongWon Kim
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2020-12-23

Review 6.  Diagnostic and Therapeutic Strategy in Anaplastic (Malignant) Meningioma, CNS WHO Grade 3.

Authors:  Vincenzo Di Nunno; Caterina Giannini; Sofia Asioli; Alfredo Conti; Julia Furtner; Damiano Balestrini; Alicia Tosoni
Journal:  Cancers (Basel)       Date:  2022-09-26       Impact factor: 6.575

7.  External validation and recalibration of an incidental meningioma prognostic model - IMPACT: protocol for an international multicentre retrospective cohort study.

Authors:  Abdurrahman I Islim; Christopher P Millward; Rory J Piper; Daniel M Fountain; Shaveta Mehta; Ruwanthi Kolamunnage-Dona; Usama Ali; Shelli Diane Koszdin; Theo Georgious; Samantha J Mills; Andrew R Brodbelt; Ryan K Mathew; Thomas Santarius; Michael D Jenkinson
Journal:  BMJ Open       Date:  2022-01-18       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.